NUWE
Nuwellis, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.78
+6.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.0M | 8.3M | 8.7M | 8.9M | 8.5M |
| Cost of Revenue | 2.7M | 3.1M | 2.9M | 3.9M | 3.8M |
| Gross Profit | 6.3M | 5.1M | 5.8M | 5.0M | 4.8M |
| Operating Expenses | |||||
| R&D Expense | 4.0M | 2.7M | 3.2M | 5.4M | 4.3M |
| SG&A Expense | 15.0M | 13.5M | — | 17.2M | 17.6M |
| General & Admin Expense | 3.7M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 13.6M | — | 75.0K |
| Total Operating Expenses | 19.0M | 16.2M | 16.8M | 22.6M | 21.9M |
| Cost and Expenses | 21.7M | 19.4M | 19.7M | 26.5M | 25.7M |
| Operating Income (EBIT) | (12.7M) | (11.1M) | (11.0M) | (17.6M) | (17.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | 10.6M | 5.6M | 3.5M | 9.2M |
| Net Interest Income | — | (10.6M) | (5.6M) | (3.5M) | (9.2M) |
| Other Non-Op Income/Expense | 1.6M | (6.4M) | (172.0K) | (2.6M) | 2.7M |
| Non-Operating Income (excl Interest) | (4.9M) | (4.1M) | (150.0K) | (912.0K) | (11.9M) |
| EBT (Pre-Tax Income) | (11.1M) | (17.5M) | (11.2M) | (20.2M) | (14.5M) |
| Income Tax Expense | — | 5.0K | 5.0K | 8.0K | 9.0K |
| Bottom Line | |||||
| Net Income | (11.1M) | (17.5M) | (11.2M) | (20.2M) | (14.5M) |
| Earnings from Cont. Ops | (11.1M) | (17.5M) | (11.2M) | (20.2M) | (14.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.1M) | (17.5M) | (10.6M) | (22.6M) | (14.5M) |
| Per Share | |||||
| Basic EPS | ($132.69) | ($25.39) | ($280.00) | ($12,602.45) | ($102,268.25) |
| Diluted EPS | ($132.69) | ($25.39) | ($280.00) | ($12,602.45) | ($102,268.25) |
| Revenue Per Share | $49.73 | $41.94 | $230.48 | $5,527.66 | $60,149.87 |
| Shares | |||||
| Basic Shares Outstanding | 181243 | 197184 | 37921 | 1604 | 142 |
| Diluted Shares Outstanding | 181243 | 197184 | 37921 | 1604 | 142 |
| Profitability Metrics | |||||
| EBITDA | (7.4M) | (6.5M) | (10.5M) | (16.4M) | (4.9M) |
| D&A | 442.0K | 417.0K | 310.0K | 362.0K | 372.0K |
| EBIT | (7.8M) | (7.0M) | (10.8M) | (16.7M) | (5.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026